Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2006 Jan 30;94(2):195-9.

mTOR signaling: implications for cancer and anticancer therapy.

Author information

  • 1Department of Biochemistry, McGill Cancer Centre, McGill University, 3655 Promenade Sir William Osler, Montreal, QUE, Canada.

Abstract

Mounting evidence links deregulated protein synthesis to tumorigenesis via the translation initiation factor complex eIF4F. Components of this complex are often overexpressed in a large number of cancers and promote malignant transformation in experimental systems. mTOR affects the activity of the eIF4F complex by phosphorylating repressors of the eIF4F complex, the eIF4E binding proteins. The immunosuppressant rapamycin specifically inhibits mTOR activity and retards cancer growth. Importantly, mutations in upstream negative regulators of mTOR cause hamartomas, haemangiomas, and cancers that are sensitive to rapamycin treatment. Such mutations lead to increased eIF4F formation and consequently to enhanced translation initiation and cell growth. Thus, inhibition of translation initiation through targeting the mTOR-signalling pathway is emerging as a promising therapeutic option.

PMID:
16404421
[PubMed - indexed for MEDLINE]
PMCID:
PMC2361102
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk